Truepoint Inc. Acquires 230 Shares of Eli Lilly and Company (NYSE:LLY)

Truepoint Inc. increased its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 99.1% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 462 shares of the company’s stock after purchasing an additional 230 shares during the period. Truepoint Inc.’s holdings in Eli Lilly and Company were worth $409,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Jim Saulnier & Associates LLC bought a new position in shares of Eli Lilly and Company during the third quarter valued at approximately $210,000. KKM Financial LLC boosted its stake in Eli Lilly and Company by 8.2% in the third quarter. KKM Financial LLC now owns 2,941 shares of the company’s stock valued at $2,606,000 after acquiring an additional 222 shares in the last quarter. Algert Global LLC boosted its stake in Eli Lilly and Company by 2,059.9% in the third quarter. Algert Global LLC now owns 10,886 shares of the company’s stock valued at $9,644,000 after acquiring an additional 10,382 shares in the last quarter. Kingsview Wealth Management LLC boosted its stake in Eli Lilly and Company by 3.5% in the third quarter. Kingsview Wealth Management LLC now owns 54,679 shares of the company’s stock valued at $48,442,000 after acquiring an additional 1,849 shares in the last quarter. Finally, Cerity Partners LLC boosted its stake in Eli Lilly and Company by 9.4% in the third quarter. Cerity Partners LLC now owns 580,520 shares of the company’s stock valued at $512,568,000 after acquiring an additional 50,091 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction dated Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the sale, the chief accounting officer now owns 5,480 shares in the company, valued at $4,402,522.40. This trade represents a 14.11 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.13% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

LLY has been the subject of several recent analyst reports. Morgan Stanley restated an “overweight” rating and issued a $1,106.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, August 27th. Cantor Fitzgerald restated an “overweight” rating and issued a $885.00 target price on shares of Eli Lilly and Company in a research note on Monday, September 16th. BMO Capital Markets raised their target price on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Truist Financial raised their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a research note on Thursday, October 10th. Finally, Barclays decreased their price target on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a report on Thursday, October 31st. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,007.94.

Eli Lilly and Company Trading Down 0.3 %

Shares of Eli Lilly and Company stock opened at $748.01 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97. The firm has a fifty day moving average price of $865.01 and a 200 day moving average price of $869.65. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53. The stock has a market cap of $710.10 billion, a PE ratio of 80.87, a price-to-earnings-growth ratio of 2.84 and a beta of 0.43.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). The firm had revenue of $11.44 billion for the quarter, compared to analyst estimates of $12.09 billion. Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The firm’s quarterly revenue was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.10 EPS. Equities research analysts predict that Eli Lilly and Company will post 13.2 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.70%. Eli Lilly and Company’s dividend payout ratio is presently 56.22%.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.